Enlight Medical is developing invasive and non-invasive BCIs to help replace, restore, or improve human functions.
Enlight Medical has partnered with Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, to accelerates commercial availability of Seer’s Proteograph Product Suite to the rapidly expanding Chinese life sciences and clinical markets.
Enlight Medical Technologies (Shanghai) Co., Ltd. is a solidly and rapidly growing international Chinese medical device platform company with a myriad of innovative strengths. Powered by acute sensitivity to clinical and market needs, and with the world’s most advanced technological innovations as our core driving force, we are committed to creating world-class high-quality products. Through the judicious fusion of independent R&D and resource integration, we aspire to continuously serve the cause of human health oriented by clinical needs.
2021年11月3日,应脉医疗科技(上海)有限公司的NovoClasp®经导管二尖瓣夹及可操控导引导管系统在首都医科大学附属北京安贞医院完成首例人体植入。本例手术由首都医科大学附属北京安贞医院院长张宏家教授、中国医学科学院阜外医院吴永健教授现场指导,首都医科大学附属北京安贞医院心脏瓣膜病介入中心宋光远教授团队、超声科何怡华教授团队完成,香港亚洲心脏中心林逸贤教授提供远程辅助,为一位高龄重度二尖瓣反流的患者成功实施微创介入二尖瓣缘对缘修复手术。本例手术的成功标志着NovoClasp®二尖瓣修复系统顺利开展首次人体临床研究入组。
2021年10月18日,应脉医疗宣布完成数亿人民币B轮融资,本轮融资由国投招商、海松资本及前海母基金共同领投,楹联健康基金跟投,原股东高瓴创投、惠每资本、真格基金、辰德资本继续增持。
2021年9月13日~9月17日,中国结构周国际频道特别推出“Device To World中国器械走向世界——创新论坛圆桌会”。作为中国结构周首个医械国际交流论坛,通过圆桌讨论的形式,让全球的专家学者认识和了解中国原创器械的风采与优势。会上,NovoClasp™二尖瓣系统作为本场首发国产器械惊艳亮相,受到了国内外专家的关注与褒赞。
@Copyright 2020-2022 Enlight Medical Limited All rights reserved 沪ICP备20012889号-2